[Post-licensure safety surveillance for Prevenar 13® in France]. / Bilan français des effets indésirables du vaccin Prévenar 13®.
Arch Pediatr
; 24(5): 439-444, 2017 May.
Article
em Fr
| MEDLINE
| ID: mdl-28242152
ABSTRACT
OBJECTIVE:
To describe the profile and the incidence of adverse events (AEs) reported with Prevenar 13® since its commercialization.METHOD:
Analysis of all adverse events reported with Prevenar 13® in France between 1st July 2010 and 31 October 2014.RESULTS:
In 4 years and 4 months, 376 AEs, including 252 severe (67%), were recorded, 83 of which occurred following an injection of Prevenar 13® alone 39 cutaneous AEs, 16 neurological AEs, four cases of collapse or shock, nine cases of fever, and one of thrombocytopenia. For the serious AEs, the outcome was favorable in 88% of cases and none of the 12 reported deaths were attributed to a side effect of vaccination. Fifty-nine cases of pneumococcal disease that suggest an ineffective vaccine were reported, but only 16 can be considered as a real failure of the vaccination.DISCUSSION:
In many cases, Prevenar 13® was administered on the same day as a hexavalent vaccine with which the AEs reported were expected. The profile of AEs reported following Prevenar 13® alone is similar to that seen with Prevenar 7®.CONCLUSION:
Since its release in 2010, the Prevenar 13® pharmacovigilance survey, which includes more than 11,800,000 distributed doses, did not show any new information in terms of tolerance safety.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Pneumonia Pneumocócica
/
Vigilância de Produtos Comercializados
/
Aprovação de Drogas
/
Vacinas Pneumocócicas
/
Imunogenicidade da Vacina
/
Meningite Pneumocócica
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
/
Screening_studies
Limite:
Child
/
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
/
Newborn
País/Região como assunto:
Europa
Idioma:
Fr
Ano de publicação:
2017
Tipo de documento:
Article